University of Kentucky joins TriNetX

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

THE UNIVERSITY OF KENTUCKY joined the TriNetX network for its clinical trial design and clinical research. Pharmaceutical researchers will gain access to the university’s clinical data through TriNetX’s network of healthcare institutions representing over 37 million patients in the U.S. and Europe to support clinical study and protocol design, site selection, and patient recruitment across...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

The NHS-Galleri trial presented at ASCO was the largest, prospective, randomized trial of a multicancer early detection test (MCED) to date. The study enrolled approximately 143,000 asymptomatic adults (ages 50-77) and was the first of its kind to assess clinical utility of an MCED test for cancer screening. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login